Faslodex Post Marketing Surveillance
Study identifier:D6997L00018
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Faslodex Post Marketing Surveillance
Medical condition
Breast Cancer
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
Female
Actual Enrollment
42
Study type
Observational
Age
0 Years - 150 Years
Date
Study Start Date: 01 Jan 2009
Primary Completion Date: 01 Oct 2013
Study Completion Date: 01 Oct 2013
Study design
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -
Verification:
Verified 01 Oct 2014 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| 1 Postmenopausal women with locally advanced or metastatic breast cancer who have failed 2 or more prior hormone therapies, or were intolerant to prior hormone therapy and have no endocrine therapeutic options. | - |
